Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALURNASDAQ:DRIOOTCMKTS:GTHPNASDAQ:PYPD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.78-5.9%$2.67$2.15▼$88.75$20.70M-0.58769,175 shs149,920 shsDRIODarioHealth$0.72+0.3%$0.68$0.50▼$1.76$31.64M1.55277,437 shs94,056 shsGTHPGuided Therapeutics$0.14+12.0%$0.10$0.06▼$0.23$11.05M0.2115,484 shs2,680 shsPYPDPolyPid$2.78-0.4%$2.71$2.30▼$4.67$28.32M1.2516,481 shs16,092 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies-6.53%-12.43%+25.05%-21.80%-93.19%DRIODarioHealth+0.28%+9.09%-10.00%+4.35%-58.62%GTHPGuided Therapeutics+12.00%+12.00%+27.85%+5.26%+73.91%PYPDPolyPid-0.39%+1.42%+1.42%-7.06%-40.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALURAllurion Technologies3.3952 of 5 stars3.55.00.00.02.43.30.6DRIODarioHealth1.853 of 5 stars3.31.00.00.02.30.81.3GTHPGuided TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APYPDPolyPid1.5674 of 5 stars3.63.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALURAllurion Technologies 3.00Buy$22.83722.53% UpsideDRIODarioHealth 2.67Moderate Buy$2.00177.78% UpsideGTHPGuided Therapeutics 0.00N/AN/AN/APYPDPolyPid 3.25Buy$11.33307.82% UpsideCurrent Analyst Ratings BreakdownLatest GTHP, PYPD, DRIO, and ALUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025DRIODarioHealthLitchfield Hills ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/14/2025PYPDPolyPidHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/27/2025ALURAllurion TechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.50 ➝ $2.503/21/2025ALURAllurion TechnologiesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/21/2025ALURAllurion TechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.503/11/2025DRIODarioHealthStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $2.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALURAllurion Technologies$32.11M0.64N/AN/A($36.95) per share-0.08DRIODarioHealth$28.03M1.13N/AN/A$2.14 per share0.34GTHPGuided Therapeutics$100K110.47N/AN/A($0.13) per share-1.08PYPDPolyPidN/AN/AN/AN/A$0.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALURAllurion Technologies-$80.61M-$12.50N/AN/AN/A-71.24%N/A-56.75%8/12/2025 (Estimated)DRIODarioHealth-$59.43M-$0.56N/AN/AN/A-205.62%-72.16%-40.74%N/AGTHPGuided Therapeutics-$3.49M-$0.05N/A∞N/AN/AN/A-151.93%8/12/2025 (Estimated)PYPDPolyPid-$29.02M-$4.30N/A∞N/AN/A-624.10%-129.28%N/ALatest GTHP, PYPD, DRIO, and ALUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GTHPGuided TherapeuticsN/A-$0.01N/A-$0.01N/AN/A5/14/2025Q1 2025ALURAllurion Technologies-$1.53$0.43+$1.96$0.20$5.50 million$5.58 million5/14/2025Q1 2025DRIODarioHealth-$0.07-$0.14-$0.07-$0.14$7.48 million$6.75 million5/14/2025Q1 2025PYPDPolyPid-$0.80-$0.70+$0.10-$0.70N/AN/A3/31/2025Q4 2024GTHPGuided TherapeuticsN/A-$0.02N/A-$0.02N/AN/A3/26/2025Q4 2024ALURAllurion Technologies-$5.00-$7.00-$2.00-$7.95$5.60 million$5.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALURAllurion TechnologiesN/AN/AN/AN/AN/ADRIODarioHealthN/AN/AN/AN/AN/AGTHPGuided TherapeuticsN/AN/AN/AN/AN/APYPDPolyPidN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALURAllurion TechnologiesN/A2.332.09DRIODarioHealth0.351.571.32GTHPGuided TherapeuticsN/A0.170.07PYPDPolyPid0.081.311.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALURAllurion Technologies21.39%DRIODarioHealth33.39%GTHPGuided Therapeutics9.69%PYPDPolyPid26.47%Insider OwnershipCompanyInsider OwnershipALURAllurion Technologies22.40%DRIODarioHealth10.90%GTHPGuided Therapeutics66.83%PYPDPolyPid24.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALURAllurion Technologies5017.46 million2.01 millionOptionableDRIODarioHealth20043.95 million28.47 millionOptionableGTHPGuided Therapeutics578.91 million21.67 millionNot OptionablePYPDPolyPid8010.19 million7.67 millionNo DataGTHP, PYPD, DRIO, and ALUR HeadlinesRecent News About These CompaniesPolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025May 20, 2025 | globenewswire.comReviewing PolyPid (NASDAQ:PYPD) and Tenon Medical (NASDAQ:TNON)May 19, 2025 | americanbankingnews.comPolyPid Ltd (PYPD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesMay 16, 2025 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comPolyPid Ltd. (PYPD) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comPolyPid Completes Enrollment in Phase 3 Trial of D-PLEX100May 14, 2025 | tipranks.comPolyPid Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | globenewswire.comA Look Ahead: PolyPid's Earnings ForecastMay 13, 2025 | benzinga.comPolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025April 29, 2025 | globenewswire.comPolyPid to Participate in The Citizens Life Sciences ConferenceApril 22, 2025 | globenewswire.comPolyPid management to meet with OppenheimerApril 17, 2025 | markets.businessinsider.comBarclays Reaffirms Their Hold Rating on PolyPid (PYPD)March 25, 2025 | markets.businessinsider.comPolyPid completes enrollment in SHIELD II Phase 3 trial for D-PLEX100March 12, 2025 | markets.businessinsider.comCraig-Hallum Remains a Buy on PolyPid (PYPD)March 12, 2025 | markets.businessinsider.comPolyPid Completes Enrollment in Phase 3 Trial for Surgical Infection PreventionMarch 11, 2025 | tipranks.comPolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsMarch 11, 2025 | globenewswire.comPolyPid to Participate in the 37th Annual ROTH ConferenceMarch 3, 2025 | globenewswire.comPolyPid Ltd (PYPD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D CostsFebruary 13, 2025 | finance.yahoo.comPolyPid targets SHIELD II trial completion with top-line results in Q2 2025February 12, 2025 | msn.comPolyPid (PYPD) Gets a Buy from JMP SecuritiesFebruary 12, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGTHP, PYPD, DRIO, and ALUR Company DescriptionsAllurion Technologies NYSE:ALUR$2.78 -0.17 (-5.90%) Closing price 05/23/2025 03:58 PM EasternExtended Trading$2.86 +0.08 (+3.03%) As of 05/23/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.DarioHealth NASDAQ:DRIO$0.72 +0.00 (+0.28%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.72 0.00 (-0.14%) As of 05/23/2025 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.Guided Therapeutics OTCMKTS:GTHP$0.14 +0.02 (+12.00%) As of 05/23/2025 03:57 PM EasternGuided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.PolyPid NASDAQ:PYPD$2.78 -0.01 (-0.39%) Closing price 05/23/2025 03:50 PM EasternExtended Trading$2.78 +0.00 (+0.04%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
